Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Hessel, Luc
2008.
The contribution of vaccine manufacturers to the establishment of vaccination policies.
Journal of Public Health,
Vol. 16,
Issue. 4,
p.
299.
Usher, Cara
Tilson, Lesley
Olsen, Jens
Jepsen, Martin
Walsh, Cathal
and
Barry, Michael
2008.
Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
Vaccine,
Vol. 26,
Issue. 44,
p.
5654.
Trollfors, Birger
2008.
Human papillomavirus vaccines: an outsider’s point of view.
Expert Review of Vaccines,
Vol. 7,
Issue. 8,
p.
1131.
Szucs, Thomas D.
Largeron, Nathalie
Dedes, Konstantin J.
Rafia, Rachid
and
Bénard, Stève
2008.
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Current Medical Research and Opinion,
Vol. 24,
Issue. 5,
p.
1473.
Annemans, Lieven
Rémy, Vanessa
Lamure, Emilie
Spaepen, Erik
Lamotte, Mark
Muchada, Jean-Paul
and
Largeron, Nathalie
2008.
Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Journal of Medical Economics,
Vol. 11,
Issue. 1,
p.
135.
Kim, Jane J.
Brisson, Marc
Edmunds, W. John
and
Goldie, Sue J.
2008.
Modeling Cervical Cancer Prevention in Developed Countries.
Vaccine,
Vol. 26,
Issue. ,
p.
K76.
Castellsagué, Xavier
San Martín, María
Cortés, Javier
González, Antonio
and
Remy, Vanessa
2008.
Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6, 11, 16 y 18 en las enfermedades asociadas al VPH en España.
Progresos de Obstetricia y Ginecología,
Vol. 51,
Issue. 9,
p.
520.
Aubin, François
Prétet, Jean‐Luc
Jacquard, Anne‐Carole
Saunier, Maelle
Carcopino, Xavier
Jaroud, Fatiha
Pradat, Pierre
Soubeyrand, Benoît
Leocmach, Yann
Mougin, Christiane
and
Riethmuller, Didier
2008.
Human Papillomavirus Genotype Distribution in External Acuminata Condylomata: A Large French National Study (EDiTH IV).
Clinical Infectious Diseases,
Vol. 47,
Issue. 5,
p.
610.
Dasbach, Erik J
Largeron, Nathalie
and
Elbasha, Elamin H
2008.
Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model.
Expert Review of Pharmacoeconomics & Outcomes Research,
Vol. 8,
Issue. 5,
p.
491.
Cortés, Javier
Vilaplana, Eduardo
Miranda, Pilar
Ferret, Gabriel
Andía, Daniel
Ramón y Cajal, José Manuel
and
Antonio Vidart, José
2009.
Vacuna frente al virus del papiloma humano y cribado de cáncer de cuello de útero.
Progresos de Obstetricia y Ginecología,
Vol. 52,
Issue. 6,
p.
361.
Puig-Junoy, Jaume
and
Lopez-Valcarcel, Beatriz G.
2009.
Economic evaluations of massive HPV vaccination: Within-study and between study variations in incremental cost per QALY gained.
Preventive Medicine,
Vol. 48,
Issue. 5,
p.
444.
Thiry, Nancy
De Laet, Chris
Hulstaert, Frank
Neyt, Mattias
Huybrechts, Michel
and
Cleemput, Irina
2009.
Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening.
International Journal of Technology Assessment in Health Care,
Vol. 25,
Issue. 02,
p.
161.
Riethmuller, D.
Prétet, J.-L.
Denis, F.
Aubin, F.
Pradat, P.
Clavel, C.
Dachez, R.
Gondry, J.
Carcopino, X.
and
Mougin, C.
2009.
Modélisation de l’impact de la vaccination HPV quadrivalente en France.
Journal de Gynécologie Obstétrique et Biologie de la Reproduction,
Vol. 38,
Issue. 5,
p.
389.
Zechmeister, Ingrid
Blasio, Birgitte Freiesleben de
Garnett, Geoff
Neilson, Aileen Rae
and
Siebert, Uwe
2009.
Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria.
Vaccine,
Vol. 27,
Issue. 37,
p.
5133.
Hillemanns, Peter
Petry, Karl Ulrich
Largeron, Nathalie
McAllister, Ruth
Tolley, Keith
and
Büsch, Katharina
2009.
Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany.
Journal of Public Health,
Vol. 17,
Issue. 2,
p.
77.
Annemans, Lieven
Rémy, Vanessa
Oyee, James
and
Largeron, Nathalie
2009.
Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium.
PharmacoEconomics,
Vol. 27,
Issue. 3,
p.
231.
Anonychuk, Andrea M
Bauch, Chris T
Merid, Maraki Fikre
Van Kriekinge, Georges
and
Demarteau, Nadia
2009.
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
BMC Public Health,
Vol. 9,
Issue. 1,
Jeurissen, Sarah
and
Makar, Amin
2009.
Epidemiological and Economic Impact of Human Papillomavirus Vaccines.
International Journal of Gynecological Cancer,
Vol. 19,
Issue. 4,
p.
761.
Marra, Fawziah
Cloutier, Karine
Oteng, Bridgette
Marra, Carlo
and
Ogilvie, Gina
2009.
Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine.
PharmacoEconomics,
Vol. 27,
Issue. 2,
p.
127.
Mennini, F.S.
Giorgi Rossi, P.
Palazzo, F.
and
Largeron, N.
2009.
Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Gynecologic Oncology,
Vol. 112,
Issue. 2,
p.
370.